BioCentury
ARTICLE | Clinical News

FibroGen surges on Phase II pamrevlumab data in IPF

August 8, 2017 12:25 AM UTC

FibroGen Inc. (NASDAQ:FGEN) gained $20.45 (61%) to $53.85 in after-hours trading Monday after it said pamrevlumab (FG-3019) met the primary endpoint in a Phase II trial to treat idiopathic pulmonary fibrosis. Specifically, pamrevlumab as monotherapy led to a lower mean decline in forced vital capacity (FVC) percent predicted from baseline to week 48 compared to placebo (2.85% vs. 7.17%, p=0.0331). Additionally, patients treated with pamrevlumab had a mean decrease in FVC of 129 mL from baseline to week 48 vs. 308 mL for placebo (p=0.0249).

The company also said that pamrevlumab plus IPF drugs Esbriet pirfenidone from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Ofev nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany) were well tolerated in the active-controlled substudies of the trial...